Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo.

American journal of hematology - 1 Apr 2026

Xiong Shengen, Wais Tamara, Varga Cecilia, Schueller Christina, Achyutuni Sarada, Kralovics Robert

Abstract excerpt

Calreticulin (CALR) mutations are prevalent in 20%-30% of patients with BCR::ABL1-negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease-initiating MPN progenitors, represents an ideal target for curative immunotherapies including monoclonal antibodies, bispecific T cell engaging...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Calreticulin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to F3 gene

Share to Mice, Transgenic

Share to Mutation

Share to Myeloproliferative Disorders

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 41532194
DOI: 10.1002/ajh.70206
PMCID: PMC12994124

Genes

ABL1
BCR
CALR
CD4
F3
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo.PMID 41532194Read ↗

Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN.Semantic proximity Read ↗

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.Semantic proximity Read ↗

CAR-T Targeting of Mutant Calreticulin Establishes a Potentially Curative Stem Cell-Directed Therapy for Myeloproliferative NeoplasmsSemantic proximity Read ↗

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.Semantic proximity Read ↗

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosisSemantic proximity Read ↗

Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.Semantic proximity Read ↗

Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.Semantic proximity Read ↗

Discovery of INCA033989, a Monoclonal Antibody That Selectively Antagonizes Mutant Calreticulin Oncogenic Function in Myeloproliferative Neoplasms (MPNs)Semantic proximity Read ↗

Hematopoietic expression of a chimeric murine‐human CALR oncoprotein allows the assessment of anti‐CALR antibody immunotherapies in vivoSemantic proximity Read ↗

INCA033989: the first shot on goal for MPNs?Semantic proximity Read ↗

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.Semantic proximity Read ↗

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative NeoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.